Legend Biotech (NASDAQ: LEGN) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Legend Biotech soared for a 5th straight day on Monday, climbing 18.42 percent to close at $25.07 apiece, as investors took ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...